The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 26 open trials.
In 109 locations
What is a Clinical Trial?
There are currently 26 open trials
- Belantamab mafodotin plus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-8)
- Isatuximab in combination with lenalidomide and dexamethasone for high-risk smouldering myeloma (ITHACA)
- Teclistamab combination treatments for myeloma
- Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIa)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIb)
- Teclistamab for relapsed and refractory myeloma
- JNJ-68284528 CART-cell therapy for relapsed and refractory myeloma
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating RO5126766 for the treatment of refractory myeloma patients
- Understanding bone pain in myeloma
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- CC-92480 for relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Observational evaluation of myeloma patients (PREAMBLE)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Belantamab mafodotin plus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-8)
Treatments:
Belantamab Mafodotin (GSK2857916)
Pomalidomide (Imnovid®)
Dexamethasone
Bortezomib (Velcade®)
Myeloma stage:
Relapsed, Refractory
Trial phase:
III
Summary:
This trial is investigating how the safety and effectiveness of belantamab mafodotin (Blenrep), pomalidomide (Imnovid) and dexamethasone (BPd) compares to pomalidomide, bortezomib (Velcade) and dexamethasone (PVd) for the treatment of relapsed and/or refractory myeloma.
Locations:
Derriford Hospital, Plymouth
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have had at least one previous treatment, including lenalidomide (Revlimid).
What's involved?:
Patients will be randomised to receive either BPd (group A) or PVd (group B).
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
Patients will be followed up for up to 7 years.
Clinical Information
(for Medical Professionals):
A randomised, open-label, Phase III trial evaluating the safety and efficacy of belantamab mafodotin, pomalidomide and dexamethasone (BPd) compared to pomalidomide, bortezomib and dexamethasone (PVd) in relapsed and/or refractory myeloma. For more information, click here.
Healthcare professionals may be able to request access to belantamab mafodotin through an expanded access programme for multiply relapsed and/or refractory patients who do not meet the inclusion criteria for this trial.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk